Research Studies

In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged > 18 years 4. A current or ex-smoker with a > 30 pack-year history of smoking and mild or worse sputum cytologic atypia, OR history of non-small cell lung cancer (stage I, II, or IIIA) with > 10 pack-year history of smoking and no evidence of active disease at least 1 year after definitive treatment, OR history of head and neck cancer (stage I, II, III, or IVA) with > 10 pack-year history of smoking and no evidence of active disease at least 1 year after definitive treatment. An ex-smoker is defined as no tobacco use in the prior 12 months 5. Endobronchial dysplasia (score > 4) on screening bronchoscopy 6. Total granulocyte count > 1500 7. Platelet count > 100,000 8. Serum creatinine < 1.5 mg/dL 9. Total bilirubin < 2.0 mg/dL 10. Transaminases and alkaline phosphatase < 2.5x upper limit of normal (ULN) 11. Albumin > 2.5 mg/dL 12. ECOG performance status &#8804; 1 (Appendix 1) 13. Participants must be able and willing to undergo three bronchoscopies: before, after four doses of nivolumab (8 weeks), and after 6 months

N/A